Abiomed Inc. (NASDAQ:ABMD) CEO Michael R. Minogue sold 28,039 shares of the firm’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $127.07, for a total value of $3,562,915.73. Following the completion of the transaction, the chief executive officer now owns 215,488 shares in the company, valued at $27,382,060.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Abiomed Inc. (NASDAQ:ABMD) opened at 123.53 on Friday. Abiomed Inc. has a one year low of $67.81 and a one year high of $127.86. The company has a market capitalization of $5.29 billion, a PE ratio of 131.41 and a beta of 0.89. The company has a 50-day moving average price of $121.06 and a 200-day moving average price of $106.47.
Abiomed (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. The firm had revenue of $103 million for the quarter, compared to analyst estimates of $97.23 million. Abiomed had a net margin of 11.75% and a return on equity of 11.86%. The business’s quarterly revenue was up 40.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.20 earnings per share. Analysts expect that Abiomed Inc. will post $1.17 earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Abiomed from a “buy” rating to a “hold” rating in a research note on Friday, August 12th. Jefferies Group raised their price target on Abiomed from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Abiomed presently has a consensus rating of “Buy” and a consensus price target of $115.59.
Several large investors have recently made changes to their positions in the stock. BB&T Securities LLC raised its stake in shares of Abiomed by 0.3% in the first quarter. BB&T Securities LLC now owns 4,385 shares of the company’s stock worth $415,000 after buying an additional 12 shares during the period. Calvert Investment Management Inc. raised its stake in shares of Abiomed by 0.9% in the second quarter. Calvert Investment Management Inc. now owns 2,242 shares of the company’s stock worth $245,000 after buying an additional 20 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Abiomed by 1.3% in the first quarter. Glenmede Trust Co. NA now owns 3,737 shares of the company’s stock worth $353,000 after buying an additional 48 shares during the period. RMB Capital Management LLC raised its stake in shares of Abiomed by 0.5% in the second quarter. RMB Capital Management LLC now owns 10,200 shares of the company’s stock worth $1,115,000 after buying an additional 50 shares during the period. Finally, WFG Advisors LP raised its stake in shares of Abiomed by 0.7% in the second quarter. WFG Advisors LP now owns 7,581 shares of the company’s stock worth $829,000 after buying an additional 51 shares during the period. 93.65% of the stock is currently owned by hedge funds and other institutional investors.
Abiomed Company Profile
Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.